Nurexone Biologic Inc. has completed a pre-IND meeting with the FDA in connection with the manufacturing, preclinical and clinical development plan of Exopten. Exopten is being developed to be a minimally invasive Exotherapy product for spinal cord injuries given intranasally and yielding neuron regeneration and rewiring in traumatically damaged spinal cords.

Nurexone Biologic Inc. is developing Exopten as a minimally invasive Exotherapy for spinal cord injuries (SCI). The company's platform produces and loads exosomes with pharmaceutical cargo, targeting SCI intranasally in the case of lead product Exopten.